SecSonar.com

Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Fulcrum Therapeutics, Inc. (FULC) is a Biotechnology company based in US with a market capitalization of $377.7M. Free cash flow was negative at -$60.4M. This page tracks FULC's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 45 employees · IPO Jul 18, 2019

Valuation

Valuation & price

$6.69 · as of May 17, 2026 · -54.2% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.08

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$13.80$8.51$3.22Jul 25Dec 25Jul 26Jul 7, 25$7.02Jul 9, 25$7.91Jul 11, 25$7.83Jul 15, 25$7.84Jul 17, 25$7.94Jul 21, 25$7.10Jul 23, 25$7.91Jul 25, 25$7.81Jul 29, 25$7.59Jul 31, 25$6.73Aug 4, 25$6.96Aug 6, 25$6.94Aug 11, 25$6.34Aug 13, 25$6.85Aug 15, 25$6.82Aug 19, 25$6.61Aug 21, 25$6.52Aug 25, 25$6.41Aug 27, 25$6.63Aug 29, 25$6.48Sep 3, 25$6.52Sep 5, 25$7.66Sep 9, 25$7.24Sep 11, 25$6.99Sep 16, 25$7.30Sep 18, 25$7.54Sep 22, 25$7.45Sep 24, 25$8.25Sep 26, 25$8.84Sep 30, 25$9.20Oct 2, 25$9.51Oct 6, 25$9.50Oct 8, 25$9.63Oct 10, 25$8.99Oct 14, 25$8.69Oct 16, 25$9.29Oct 21, 25$9.70Oct 23, 25$8.95Oct 27, 25$9.65Oct 29, 25$9.36Oct 31, 25$8.75Nov 4, 25$8.37Nov 6, 25$7.65Nov 10, 25$7.67Nov 12, 25$8.36Nov 14, 25$8.65Nov 18, 25$9.73Nov 20, 25$11.06Nov 25, 25$11.54Nov 28, 25$10.94Dec 2, 25$8.95Dec 4, 25$8.76Dec 8, 25$12.99Dec 10, 25$13.80Dec 12, 25$13.00Dec 16, 25$12.50Dec 18, 25$12.16Dec 22, 25$12.78Dec 24, 25$12.01Dec 29, 25$11.99Jan 2, 26$10.92Jan 6, 26$9.99Jan 8, 26$10.11Jan 12, 26$9.51Jan 14, 26$10.36Jan 16, 26$10.14Jan 21, 26$10.42Jan 23, 26$10.75Jan 27, 26$10.94Jan 29, 26$10.94Feb 2, 26$10.72Feb 4, 26$9.90Feb 9, 26$10.23Feb 11, 26$10.87Feb 13, 26$10.63Feb 18, 26$10.94Feb 20, 26$11.00Feb 24, 26$8.58Feb 26, 26$8.73Mar 2, 26$7.81Mar 4, 26$8.35Mar 6, 26$8.17Mar 10, 26$8.01Mar 12, 26$7.63Mar 17, 26$7.43Mar 19, 26$7.04Mar 23, 26$6.89Mar 25, 26$6.98Mar 27, 26$6.73Mar 31, 26$7.67Apr 2, 26$8.04Apr 7, 26$7.83Apr 9, 26$7.91Apr 13, 26$7.73Apr 15, 26$8.25Apr 17, 26$8.29Apr 22, 26$7.75Apr 24, 26$7.84Apr 28, 26$7.44Apr 30, 26$7.13May 4, 26$7.02May 6, 26$7.11May 8, 26$7.01May 12, 26$6.96May 14, 26$7.11May 18, 26$6.09May 20, 26$6.35May 22, 26$6.57May 28, 26$6.82Jun 1, 26$6.42Jun 3, 26$3.22Jun 5, 26$3.69Jun 9, 26$3.52Jun 11, 26$3.55Jun 15, 26$3.51Jun 17, 26$3.50Jun 22, 26$3.77Jun 24, 26$3.76Jun 26, 26$3.80Jul 2, 26$3.84
$3.1452-week range$14.60
Loading valuation history…

Fundamentals

Key fundamentals

$377.7M

Market cap

—

Revenue growth (YoY)

20.8%

Gross margin

-$60.4M

Free cash flow (USD)

-$345.9M

Net debt

Net cash position

2.2%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2017 → 2025

FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$8.8MFY 2021$19.2MFY 2022$6.3MFY 2023$2.8MFY 2024$80.0MFY 2025$0.00
$0$0

Free cash flow by year

2017 → 2025

FY 2017$-22.0MFY 2018$-31.5MFY 2019$-40.3MFY 2020$-55.0MFY 2021$-80.2MFY 2022$-99.0MFY 2023$-91.5MFY 2024$-2.5MFY 2025$-60.4M
-$22M-$60.4M

Gross margin by year

2021 → 2024

FY 2021-263.7%FY 2022-1110.7%FY 2023100.0%FY 202420.8%
-263.7%20.8%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 27, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 25, 2026Filing
  • 8-K eventRestructuring Plan ApprovedJun 11, 2026Filing
  • 8-K eventRestructuring Plan ApprovedJun 4, 2026Filing
  • 8-K eventProgram DiscontinuationJun 1, 2026Filing
  • 8-K eventBusiness Update and Financial ResultsApr 27, 2026Filing
  • Quarterly report10-Q FiledApr 27, 2026Filing

Questions

Frequently asked questions

What is Fulcrum Therapeutics, Inc.'s market cap?

Fulcrum Therapeutics, Inc. (FULC) has a market capitalization of $377.7M.

What is FULC's P/E ratio?

A meaningful P/E ratio is not available for FULC — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is FULC's price-to-book (P/B) ratio?

FULC trades at 1.08 times book value per share.

Are insiders buying FULC stock?

SEC Form 4 filings show no open-market insider buys at Fulcrum Therapeutics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

PTN

Palatin Technologies, Inc.

$368M

CCCC

C4 Therapeutics, Inc.

$367.8M

PALI

Palisade Bio, Inc.

$366.3M

RGNX

REGENXBIO Inc.

$365.2M

PBYI

Puma Biotechnology, Inc.

$364.7M

IRD

Opus Genetics, Inc.

$364.7M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.